These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11217073)

  • 1. In addition to the high-density lipoprotein fraction, apolipoprotein C-III is detected in chylomicrons and the very low-density lipoprotein fraction from serum of normolipidemic cows.
    Katoh N
    J Vet Med Sci; 2001 Jan; 63(1):95-7. PubMed ID: 11217073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum concentration of apolipoprotein C-III and its greater distribution to chylomicrons than to the high-density lipoprotein fraction in a calf with hyperlipidemia.
    Yamamot M; Oohashi T; Katoh N; Oikawa S
    J Vet Med Sci; 2000 Oct; 62(10):1033-9. PubMed ID: 11073072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins.
    Le NA; Gibson JC; Ginsberg HN
    J Lipid Res; 1988 May; 29(5):669-77. PubMed ID: 3411241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins.
    Tornoci L; Scheraldi CA; Li X; Ide H; Goldberg IJ; Le NA
    J Lipid Res; 1993 Oct; 34(10):1793-803. PubMed ID: 8245727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.
    Breyer ED; Le NA; Li X; Martinson D; Brown WV
    J Lipid Res; 1999 Oct; 40(10):1875-82. PubMed ID: 10508207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
    Batal R; Tremblay M; Barrett PH; Jacques H; Fredenrich A; Mamer O; Davignon J; Cohn JS
    J Lipid Res; 2000 May; 41(5):706-18. PubMed ID: 10787431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins.
    Bukberg PR; Le NA; Ginsberg HN; Gibson JC; Rubinstein A; Brown WV
    J Lipid Res; 1985 Sep; 26(9):1047-57. PubMed ID: 4067427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.
    Fredenrich A; Giroux LM; Tremblay M; Krimbou L; Davignon J; Cohn JS
    J Lipid Res; 1997 Jul; 38(7):1421-32. PubMed ID: 9254067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a lipoprotein profile using capillary electrophoresis and mass spectrometry.
    Macfarlane RD; Bondarenko PV; Cockrill SL; Cruzado ID; Koss W; McNeal CJ; Spiekerman AM; Watkins LK
    Electrophoresis; 1997 Sep; 18(10):1796-806. PubMed ID: 9372272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human intestinal lipoproteins. Studies in chyluric subjects.
    Green PH; Glickman RM; Saudek CD; Blum CB; Tall AR
    J Clin Invest; 1979 Jul; 64(1):233-42. PubMed ID: 221544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum lipoproteins and apolipoproteins in rats with streptozotocin-induced diabetes.
    Bar-On H; Roheim PS; Eder HA
    J Clin Invest; 1976 Mar; 57(3):714-21. PubMed ID: 175093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDL 29311, a phenolic antioxidant, interferes with the interaction of apoC with VLDL: a possible explanation for its triglyceride-lowering effect.
    Sheetz MJ
    J Lipid Res; 1995 Dec; 36(12):2609-21. PubMed ID: 8847487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of serum apolipoprotein C-III concentration by enzyme-linked immunosorbent assay and its higher concentration in cows during midlactation than during the nonlactating stage.
    Yamamoto M; Katoh N; Oikawa S
    Am J Vet Res; 1998 Nov; 59(11):1358-63. PubMed ID: 9829390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.
    Baggio G; Manzato E; Gabelli C; Fellin R; Martini S; Enzi GB; Verlato F; Baiocchi MR; Sprecher DL; Kashyap ML
    J Clin Invest; 1986 Feb; 77(2):520-7. PubMed ID: 3944267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma.
    Nguyen MN; Chan DC; Dwyer KP; Bolitho P; Watts GF; Barrett PH
    J Lipid Res; 2006 Jun; 47(6):1274-80. PubMed ID: 16556931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects.
    Cohn JS; Tremblay M; Batal R; Jacques H; Veilleux L; Rodriguez C; Bernier L; Mamer O; Davignon J
    J Lipid Res; 2002 Oct; 43(10):1680-7. PubMed ID: 12364552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein C-II modifications associated with an infusion of artificial lipid particles.
    Iriyama K; Nishiwaki H; Terashima H; Tonouchi H; Miki C; Suzuki H; Carpentier YA
    JPEN J Parenter Enteral Nutr; 1988; 12(1):60-2. PubMed ID: 3125357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.